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the standard cytogenetics classiﬁcation (unfavorable, intermediate,
favorable). We then compared each of this subgroup with the
corresponding population of patients presenting the same risk
factors but owning a HLA identical sibling. In the standard risk
group (n  66), no-donor patients presented a favorable 10-year
survival (74%) compared with patients with a donor (51%) (P 
not signiﬁcant), and allo-SCT should not be recommended. In the
poor risk group (n  131), patients without a donor presented a
poor outcome (10-year OS  17%), which was not better if a
donor existed (28%) (P  .29); in these patients with a poor
outcome whatever the treatment, investigational studies should be
recommended. In the intermediate risk group (n  275), allo-SCT
offered a better outcome; the 10-year probabilities of relapse,
nonrelapse death, OS, and LFS (no donor vs donor) were 47%
versus 18% (P  .0001), 7% versus 17% (P  .02), 47% versus
63% (P  .02), and 45% versus 64% (P  .001), and the 10-year
OS was 56% versus 41% (P  .01). Allo-SCT represent a real
chance of long-term outcome and might beneﬁt from recent ad-
vances. We conclude that long-term outcome might be achieved in
some subgroups of patients and that the indication for allo-ASCT
could be assessed trough a simple classiﬁcation based on common
parameters.
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TOTAL BODY IRRADIATION (TBI) AND G-CSF-COMBINED HIGH-DOSE
CYTARABINE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOGE-
NOUS LEUKEMIA (AML) AND ADVANCED MYELODYSPLASTIC SYN-
DROME (MDS)
Mori, T.; Yokoyama, A.; Aisa, Y.; Yamane, A.; Yamazaki, R.; Naka-
zato, T.; Ikeda, Y.; Okamoto, S. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan.
The most common reason for failure in later-stage patients after
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for AML and advanced MDS is leukemic relapse, demonstrating
the inability of preparative regimen to completely eradicate leuke-
mic cells. We report the outcome of allo-HSCT for myeloid
malignancies using myeloablative preparative regimen including
TBI and high-dose cytarabine. In addition, granulocyte colony-
stimulating factor (G-CSF) was simultaneously administered with
cytarabine to increase the susceptibility of leukemic cells to cytar-
abine. Patients and Methods: Patients with myeloid malignan-
cies, including AML, AML evolving from MDS, and advanced
MDS (RAEB, RAEB-t, CMML) were eligible. For conditioning,
patients received TBI (12 Gy) followed by intravenous high-dose
cytarabine (3g/m2 every 12 hours for 4 consecutive days). Recom-
binant G-CSF (lenograstim; 5 g/kg/day) was administered intra-
venously by continuous infusion for 4 days, starting 12 hours
before the ﬁrst dose of Ara-C and continued until the last dose of
Ara-C. For the prophylaxis of acute graft-versus-host disease, cy-
closporine A or tacrolimus with or without short-term methotrex-
ate was given. Results: Seventy-nine patients were evaluable, with
a median age of 39 years (range, 15–58 years). Their diagnoses
were AML in 57, AML from MDS in 11, and MDS in 11 (RAEB
in 8, RAEB-t in 1, CMML in 1). Five-year overall survival (OS),
disease-free survival (DFS), and relapse rate (RR) were 79.1%,
76.3%, and 15.2% in AML in remission, and 41.9%, 34.4%, and
46.4% in AML not in remission. These rates were 43.6%, 43.6%,
and 0% in AML from MDS and 71.6%, 72.7%, and 10% in
advanced MDS. For AML in remission, no risk factor affecting OS
and RR was observed, whereas both high-risk karyotype abnormal-
ity and high numbers of blasts in the peripheral blood negatively
affected OS, and these 2 factors and absence of chronic GVHD
signiﬁcantly increased RR in AML not in remission. Conclusions:
These data suggest that TBI and G-CSF combined high-dose
cytarabine is a highly effective regimen for allo-HSCT for AML in
remission, AML evolving from MDS, and advanced MDS with a
notably low incidence of relapse.
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THE USE OF AUTOLOGOUS LMP2-SPECIFIC CYTOTOXIC T LYMPHO-
CYTES FOR THE TREATMENT OF RELAPSED EBV HODGKIN’S DISEASE
AND NON-HODGKIN’S LYMPHOMA
Bollard, C.M.1,3; Straathof, K.C.1; Huls, H.1; Gresik, V.3; Carrum,
G.1,2; Gottschalk, S.1,3; Gee, A.1; Brenner, M.K.1,2,3; Rooney, C.M.1,3;
Heslop, H.E.1,2,3 1. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX; 2. Methodist Hospital, Houston, TX; 3. Texas
Children’s Hospital, Houston, TX.
EBV-associated Hodgkin’s disease (HD) and some cases of
non-Hodgkins lymphoma (NHL) show type II latency express-
ing the subdominant EBV antigens EBNA1, LMP1, and LMP2,
which may serve as targets for immunotherapy approaches. In
previous studies, we used polyclonal EBV-speciﬁc CTL in pa-
tients with relapsed EBVHD and saw 2 complete and 1 partial
responses in 11 patients. Analyses of EBV-CTL lines showed
that small populations of T cells reactive against the tumor-
associated antigen LMP2 were present in most of the infused
lines, with some expansion in the peripheral blood after infu-
sion. We therefore hypothesized that CTL speciﬁcally targeting
LMP2 might have greater efﬁcacy in these patients. LMP2-
CTLs were generated from 10 patients using dendritic cells and
lymphoblastoid cell lines (LCLs) that had been genetically mod-
iﬁed to overexpress LMP2 by transduction with an
Ad5f35LMP2 vector. Polyclonal LMP2-CTL lines recognized
2–6 (median, 4) LMP2 epitopes, as determined using overlap-
ping LMP2 peptide pools in ELISPOT assays. A mean of 22.8%
(range, 5%-42.1%) of CD8 T cells bound HLA-restricted
LMP2 tetramers, compared with a mean of 0.11% (range,
0.01%-0.24%) of LMP2-tetramer positive CD8 T cells found
in CTLs generated with genetically unmodiﬁed LCLs from the
same patients. So far, 6 patients have been treated with 2 doses
of 2  107 CTL/m2 2 weeks apart. No immediate toxicity was
observed. In patients with identiﬁed LMP2 epitopes, measure-
ment of IFN secretion by CD8 T cells after stimulation with
appropriate LMP2 peptides in ELISPOT assays showed a 4- to
25-fold increase in spot-forming cells after infusions. In con-
trast, frequencies of CMV and superantigen-speciﬁc T cells did
not increase. Four patients without radiologic evidence of dis-
ease who received CTL as adjuvant therapy post-SCT or che-
motherapy remain well up to 12 months post-CTL. Two pa-
tients with measurable disease at the time of CTL infusion had
stable disease 8 weeks post-CTL. They received 2 further doses
of LMP2-CTL. One patient continues with stable disease, and
the other patient had a complete radiologic response. This
patient had a supraclavicular lymph node resection that showed
selective accumulation of LMP2 tetramer-positive cells (0.3%,
compared to 0.01% in the peripheral blood) with few residual
tumor cells. Immunotherapy with autologous LMP2-CTL is
therefore well tolerated in patients with relapsed EBV HD/
NHL, and infused LMP2-CTL cells can localize to the tumor
and induce a clinical response.
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REPAIR OF CROHN’S DISEASE WITH EMBRYONIC STEM CELLS
Feng, Z.; Arrunategui-Correa, V.; Kim, H.S.; Carrier, E. University of
California, San Diego, La Jolla, CA.
The primary objective of this work is to determine differentiation
and repair potential of murine embryonic stem cells (ES) in murine
Crohn’s disease (CD) model. Methods: Colitis was induced in
IL10/ knock-out mice using piroxicam. The colitis in this
model is patchy and progressive and leads to death unless rescue
therapy is provided. Enhanced yellow ﬂuorescent protein (EYFP)
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marked murine ES cells (R1/129) and ES-CCE without marker
ﬂuorescence protein in vitro differentiation induced by TGF- (2
ng/ml), EGF (25 ng/ml), and -FGF (100 ng/ml) for 7 days.
IL10/ mice were injected with predifferentiated ES-YFP cells
and killed at 2 months postinjection. Serial frozen sections of
colon, small intestine, and thymus were made, and EYFP staining
was double detected using a confocol microscope and determined
by immunohistochemistry using anti-GFP antibody. Results:His-
topathologic analysis demonstrated improvement in colon tissue.
Fluorescent and confocal microscopy demonstrated presence of
the ES-EYFP cells in the colon, small intestine, liver, and thymus
tissues. Anti-GFP staining was also detected in these tissues. The
EYFP signal was not detected in sham and control IL10/
knock-out mice. Immune studies by ELISA demonstrated a
TH13TH2 shift suggesting immune recovery. Conclusion: Our
results suggest that the study of differentiation and repair potential
of embryonic stem cells in pathological Crohn’s disease model may
lead to an alternative therapeutic potential for the treatment and
prevention of inﬂammatory bowel disease.
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HUMAN HEMATOPOIETIC STEM CELLS CAN BE EXPANDED EX VIVO
USING RECOMBINANT TAT-HOXB4 PROTEIN
Krosl, G.1; Giard, M.-P.1; Krosl, J.2; Humphries, R.K.3; Sauvageau,
G.2; Roy, D.C.1 1. Hopital Maisonneuve-Rosemont Research Centre,
Montreal, QC, Canada; 2. IRIC/Universite de Montreal, Montreal,
QC, Canada; 3. Terry Fox Laboratory, BC Cancer Agency, Vancouver,
BC, Canada.
In mouse bone marrow transplantation models, engineered over-
expression of HOXB4 has been one of the most potent stimulator
of hematopoietic stem cell (HSC) expansion identiﬁed to date. The
addition of soluble recombinant TAT-HOXB4 protein was also
recently reported to enable rapid in vitro expansion of murine
HSCs that retain their in vivo proliferation and differentiation
capacity. However, the expansion potential of TAT-HOXB4 has
always been tested on murine cells, and the capacity of this recom-
binant protein to expand human hematopoietic stem cells has
remained hypothetical. To determine the ability of recombinant
TAT-HOXB4 protein to promote human HSC expansion, we
performed a series of experiments using CD34 populations iso-
lated from healthy volunteers. The CD34 cell populations were
cultured for 4 days in ex vivo 15 medium supplemented with stem
cell factor (300 ng/mL) and G-CSF (50 ng/mL) in the presence or
absence of TAT-HOXB4 protein (50 nmol/L). In response to
TAT-HOXB4, total numbers of mononuclear cells demonstrated a
modest but distinct 2-fold increase compared with controls. TAT-
HOXB4 treatment had a major proliferation enhancing effect on
the more primitive cell populations such as CFU-GEMM, BFU-E,
and BFU-Meg, which numbers increased 26.5- 	 1.4-fold
(mean 	 SD), 2.2- 	 0.7-fold, and 2.1- 	 0.2-fold, respectively,
over their input values, and 19.1- 	 1.3-fold, 2.7- 	 0.7-fold, and
31- 	 3.4-fold, respectively, compared with growth factor-only
controls. In response to TAT-HOXB4, the total numbers of
CD34CD38Lin cells increased 2.1- 	 0.7-fold above their
starting numbers, compared with a 1.5- 	 0.5-fold loss of this
population in control cultures. HSC numbers were enumerated at
the beginning, and after a 4-day TAT-HOXB4 treatment period
under the same conditions using a NOD/SCID repopulation assay.
In response to 50 nM TAT-HOXB4, NOD/SCID repopulating
cell (SRC) numbers increased 2-fold over their input values, com-
pared with a 9-fold loss in control cultures without TAT-HOXB4.
These results show that recombinant TAT-HOXB4 protein, even
when combined with a limited number of hematopoietic growth
factors, has the capacity to rapidly induce ex vivo expansion of
human stem cell and progenitor cell populations. They also pro-
vide the ﬁrst evidence that TAT-HOXB4 protein could be used to




ABDOMINAL CT IN THE CLINICAL EVALUATION OF ACUTE GRAFT-
VERSUS-HOST DISEASE (GVHD) OF THE GASTROINTESTINAL TRACT:
DIFFUSE SMALL INTESTINE INVOLVEMENT IS ASSOCIATED WITH POOR
OUTCOME
Shimoni, A.; Hertz, M.; Yeshurun, M.; Portnoy, O.; Hardan, I.;
Amitai, M.; Nagler, A.; Apter, S. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
Acute GVHD is the major treatment-related complication after
allogeneic stem-cell transplantation. Acute GVHD of GI tract is a
clinical diagnosis supported by histopathologic ﬁndings. The vol-
ume of diarrhea determines disease stage and prognosis; however,
its assessment is inconvenient and inaccurate. Moreover, patients
may present with atypical symptoms, whereas GI tract biopsies
may be falsely negative due to patchy involvement or may be
contraindicated in patients with severe thrombocytopenia. This
study was designed to determine the CT features associated with
acute GI GVHD and to evaluate its role in assessment of severity
and prognosis. A total of 34 consecutive patients with symptoms
suggestive of acute GI GVHD were evaluated by abdominal CT.
Of these 34 patients, 18 had clinical stage I-II and 14 had clinical
stage III-IV by the Glucksberg criteria; 32 patients had patholog-
ical ﬁndings on CT. The most consistent ﬁnding was thickening of
the bowel wall, which was limited to the small bowel (n  11) or
large bowel (n  5) or involved both segments (n  16). Involve-
ment was diffuse or segmental. Other manifestations included
intestinal dilatation (n  11), mucosal enhancement (n  3), and
gastric wall thickening (n  7). Extraintestinal ﬁndings included
mesenteric stranding (n  22), ascites (n  13), and biliary system
abnormalities (n  11). Ten patients had urinary excretion of
orally administered gastrograﬁn, which is not normally absorbed
by an intact intestine. Diffuse thickening of the small bowel wall
and/or any involvement of the large intestine were patterns asso-
ciated with severe clinical presentation. Eleven and 14 of the 16
patients with clinical stage III-IV had these patterns, compared to
5 and 7 of the 18 patients with stage I-II, respectively (P  .03).
Overall, 19 patients responded to immunesuppressive therapy.
Nine patients are alive; 25 died, 13 of complications directly re-
lated to GVHD. Diffuse small bowel disease was associated with
poor prognosis. Only 6 of 16 patients showing this pattern re-
sponded to therapy, compared with 13 of 18 patients without this
pattern (P  .05). The cumulative incidence of GVHD-related
death was 56% and 25%, respectively (P  .05). Overall survival
was not signiﬁcantly different in the 2 groups. In conclusion,
abdominal CT may have an important role in the diagnosis of
GVHD in atypical presentations and in the prognostic evaluation.
Diffuse small intestinal disease is associated with poor response to
therapy and GVHD-related mortality. CT ﬁndings may direct the
clinician in determining the therapeutic approach.
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SAFETY AND TOLERABILITY OF ANTIBACTERIAL PROPHYLAXIS DUR-
ING THE POSTENGRAFTMENT PHASE AFTER MYELOABLATIVE HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Bubalo, J.S.; Hayes-Lattin, B.; Curtin, P.T.; Leis, J.F.Mauro, M.J.;
Simic, A.Dunn, A.; Subbiah, N.; Allen, B.; Balleison, S.; Schubach, S.;
Maziarz, R.T. Oregon Health Science University Hospital, Portland,
OR.
Background: Bacterial infections are frequent complications of
the postengraftment phase after ablative allogeneic HSCT. This
pilot study investigated the safety and tolerability of administering
antibiotic (ABX) prophylaxis from when patients tolerated PO
medications after engraftment (ANC  1500/mm3 for 2 days)
through day 100. Methods: Twenty-three engrafted allogeneic
BMT patients at OHSU, received moxiﬂoxacin (MOXI) 400 mg
po daily. Drug was started on discontinuation of any ABX used for
the treatment of pre-enrollment bacterial infection or neutropenic
fever. Rates of bacterial infection, bacteremia, and colonization
were recorded. Comparisons were made with a cohort of 60 con-
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